i
Class I indications for implantation of cardioverter defibrillator for reducing the risk of sudden death:
- chronic HF + episode of symptomatic VT + patients in whom expected survival time with good functional status is > 1 year,
- chronic HF + episode of  sustained VT + patients in whom expected survival time with good functional status is > 1 year,
- chronic HF + episode of symptomatic VF + patients in whom expected survival time with good functional status is > 1 year,
- chronic HF + episode of sustained VF + patients in whom expected survival time with good functional status is > 1 year,
- chronic ischaemic HF + NYHA Class II - III symptoms persisting despite optimal at least 3-month pharmacotherapy + LVEF < 35% + prior MI before > 40 days + patients in whom expected survival time with good functional status is > 1 year,
- chronic non-ischaemic HF + NYHA Class II - III symptoms persisting despite optimal at least 3-month pharmacotherapy + LVEF < 35% + patients in whom expected survival time with good functional status is > 1 year.